Overall, we argue that stability enforcement (through dynamics and/or plasticity) seems reasonable given current29 neuroscientific theories (e.g., Zenke, Ganguli & Gerstner 2017, "The temporal paradox of Hebbian learning and30 homeostatic plasticity."). Lastly, R3's mention that the pre-activation variableal doesn't appear in the update can be readily explained.

The backpropagation algorithm has experienced remarkable success in training large-scale artificial neural networks; however, its biological plausibility has been strongly criticized, and it remains an open question whether the brain employs supervised learning mechanisms akin to it. Here, we propose correlative information maximization between layer activations as an alternative normative approach to describe the signal propagation in biological neural networks in both forward and backward directions. This new framework addresses many concerns about the biological-plausibility of conventional artificial neural networks and the backpropagation algorithm. The coordinate descent-based optimization of the corresponding objective, combined with the mean square error loss function for fitting labeled supervision data, gives rise to a neural network structure that emulates a more biologically realistic network of multi-compartment pyramidal neurons with dendritic processing and lateral inhibitory neurons. Furthermore, our approach provides a natural resolution to the weight symmetry problem between forward and backward signal propagation paths, a significant critique against the plausibility of the conventional backpropagation algorithm. This is achieved by leveraging two alternative, yet equivalent forms of the correlative mutual information objective. These alternatives intrinsically lead to forward and backward prediction networks without weight symmetry issues, providing a compelling solution to this long-standing challenge.

Generative models capable of precisely capturing nuanced clinical features in medical images hold great promise for facilitating clinical data sharing, enhancing rare disease datasets, and efficiently synthesizing (annotated) medical images at scale. Despite their potential, assessing the quality of synthetic medical images remains a challenge. While modern generative models can synthesize visually-realistic medical images, the clinical plausibility of these images may be called into question. Domain-agnostic scores, such as FID score, precision, and recall, cannot incorporate clinical knowledge and are, therefore, not suitable for assessing clinical sensibility. Additionally, there are numerous unpredictable ways in which generative models may fail to synthesize clinically plausible images, making it challenging to anticipate potential failures and design automated scores for their detection.

Retrosynthesis is one of the domains transformed by the rise of generative models, and it is one where the problem of nonsensical or erroneous outputs (hallucinations) is particularly insidious: reliable assessment of synthetic plans is time-consuming, with automatic methods lacking. In this work, we present RetroTrim, a retrosynthesis system that successfully avoids nonsensical plans on a set of challenging drug-like targets. Compared to common baselines in the field, our system is not only the sole method that succeeds in filtering out hallucinated reactions, but it also results in the highest number of high-quality paths overall. The key insight behind RetroTrim is the combination of diverse reaction scoring strategies, based on machine learning models and existing chemical databases. We show that our scoring strategies capture different classes of hallucinations by analyzing them on a dataset of labeled retrosynthetic intermediates. This approach formed the basis of our winning solution to the Standard Industries \$1 million Retrosynthesis Challenge. To measure the performance of retrosynthesis systems, we propose a novel evaluation protocol for reactions and synthetic paths based on a structured review by expert chemists. Using this protocol, we compare systems on a set of 32 novel targets, curated to reflect recent trends in drug structures. While the insights behind our methodology are broadly applicable to retrosynthesis, our focus is on targets in the drug-like domain. By releasing our benchmark targets and the details of our evaluation protocol, we hope to inspire further research into reliable retrosynthesis.